Action WPD Pharmaceuticals - WBIO

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Dernier

0,07

Prix Achat

0,075

Prix Vente

0,19

Volume échangé

0,00 Fourchette du Jour 0,00

0,07 Plage de 52 semaines 1,125

Clôture Veille

0,07

Ouverture

Dernière Transaction

Dernière heure de transaction

Volume moyen (3 m)

11 672

Volume financier

VWAP

WPD Pharmaceuticals Provides Update On Berubicin Drug Candidate in Celebration of National Brain Cancer Day in Canada

VANCOUVER, British Columbia, Oct. 26, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE:...

WPD Pharmaceuticals Appoints New Chief Medical Officer to Lead Phase I and II Clinic Trials

VANCOUVER, British Columbia, Oct. 15, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE:...

WPD Pharmaceuticals Receives the First Prepayment of $705,000 from Total $7.4 Million Grant for Development of Berubicin, and...

VANCOUVER, British Columbia, Oct. 05, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE:...

WPD Pharmaceuticals Receives Second Prepayment of $705,000 from Total $7.4 Million Grant for Development of WPD101

VANCOUVER, British Columbia, Sept. 16, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE:...

WPD Pharmaceuticals Engages Worldwide Clinical Trials as CRO for Phase 2 Berubicin Trials

VANCOUVER, British Columbia, Sept. 09, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (“WPD” or the...

WPD Pharmaceuticals Announces New Publication Demonstrating Highly Effective Anticancer Therapy in Animals with Spontaneous T...

VANCOUVER, British Columbia, Sept. 01, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (“WPD” or the...

WPD Pharmaceuticals Enters into Collaborative Agreement for WP1122, Receives Supply and Appoints New CFO

VANCOUVER, British Columbia, Aug. 17, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (“WPD” or the...

WPD Pharmaceuticals Provides Update on WPD101, a Drug Candidate Targeting GBM Tumors

VANCOUVER, British Columbia, July 28, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (“WPD” or the...

WPD Pharmaceuticals Licensor Announces New Independent In Vitro Testing Confirms Antiviral Activity of WP1122 in Coronavirus

VANCOUVER, British Columbia, July 23, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE:...

WPD Pharmaceuticals Licensor Announces Updates on Annamycin and WP1066

VANCOUVER, British Columbia, July 06, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE:...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	-0.12	-63.1578947368	0.19	0.19	0.07	2000	0.07	CS
4	-0.12	-63.1578947368	0.19	0.19	0.07	713	0.11909897	CS
12	-0.055	-44	0.125	0.5	0.07	11672	0.1769948	CS
26	-0.055	-44	0.125	0.5	0.07	26987	0.13499481	CS
52	-1.055	-93.7777777778	1.125	1.125	0.07	28806	0.18817354	CS
156	-1.68	-96	1.75	2.125	0.07	9855	0.21995656	CS
260	-26.68	-99.738317757	26.75	36.5	0.07	36735	12.06794248	CS

WBIO - Frequently Asked Questions (FAQ)

What is the current WPD Pharmaceuticals share price?

The current share price of WPD Pharmaceuticals is $ 0,07

What is the 1 year trading range for WPD Pharmaceuticals share price?

WPD Pharmaceuticals has traded in the range of $ 0,07 to $ 1,125 during the past year

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
FNQFineqia International Inc	$ 0,01 (100,00%)	59,4k
CATCAT Strategic Metals Corporation	$ 0,01 (100,00%)	19k
NTNewterra Resources Inc	$ 0,07 (75,00%)	1 000
WINCommon Stock	$ 0,015 (50,00%)	1,52M
LCRLancaster Resources Inc	$ 0,015 (50,00%)	65k
KVMKingsview Minerals Ltd	$ 0,005 (-66,67%)	33k
CVGRCity View Green Holdings Inc	$ 0,01 (-33,33%)	880,63k
OBRNOberon Uranium Corp	$ 0,015 (-25,00%)	10,45k
AICAlphaGen Intelligence Corp	$ 0,015 (-25,00%)	2,1k
CACRKWG Resources Inc	$ 0,015 (-25,00%)	110k
WINCommon Stock	$ 0,015 (50,00%)	1,52M
CVGRCity View Green Holdings Inc	$ 0,01 (-33,33%)	880,63k
CULTCult Food Science Corp	$ 0,045 (-10,00%)	570,56k
QIMCQuebec Innovative Materials Corp	$ 0,205 (-18,00%)	564,95k
SCYBScryb Inc	$ 0,015 (0,00%)	400,5k

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

WPD Pharmaceuticals Inc (WBIO)

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

WBIO Dernières nouvelles

WPD Pharmaceuticals Provides Update On Berubicin Drug Candidate in Celebration of National Brain Cancer Day in Canada

WPD Pharmaceuticals Appoints New Chief Medical Officer to Lead Phase I and II Clinic Trials

WPD Pharmaceuticals Receives the First Prepayment of $705,000 from Total $7.4 Million Grant for Development of Berubicin, and...

WPD Pharmaceuticals Receives Second Prepayment of $705,000 from Total $7.4 Million Grant for Development of WPD101

WPD Pharmaceuticals Engages Worldwide Clinical Trials as CRO for Phase 2 Berubicin Trials

WPD Pharmaceuticals Announces New Publication Demonstrating Highly Effective Anticancer Therapy in Animals with Spontaneous T...

WPD Pharmaceuticals Enters into Collaborative Agreement for WP1122, Receives Supply and Appoints New CFO

WPD Pharmaceuticals Provides Update on WPD101, a Drug Candidate Targeting GBM Tumors

WPD Pharmaceuticals Licensor Announces New Independent In Vitro Testing Confirms Antiviral Activity of WP1122 in Coronavirus

WPD Pharmaceuticals Licensor Announces Updates on Annamycin and WP1066

WBIO - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

WPD Pharmaceuticals Inc (WBIO) Cours

WPD Pharmaceuticals Inc (WBIO)

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

WBIO Dernières nouvelles

WPD Pharmaceuticals Provides Update On Berubicin Drug Candidate in Celebration of National Brain Cancer Day in Canada

WPD Pharmaceuticals Appoints New Chief Medical Officer to Lead Phase I and II Clinic Trials

WPD Pharmaceuticals Receives the First Prepayment of $705,000 from Total $7.4 Million Grant for Development of Berubicin, and...

WPD Pharmaceuticals Receives Second Prepayment of $705,000 from Total $7.4 Million Grant for Development of WPD101

WPD Pharmaceuticals Engages Worldwide Clinical Trials as CRO for Phase 2 Berubicin Trials

WPD Pharmaceuticals Announces New Publication Demonstrating Highly Effective Anticancer Therapy in Animals with Spontaneous T...

WPD Pharmaceuticals Enters into Collaborative Agreement for WP1122, Receives Supply and Appoints New CFO

WPD Pharmaceuticals Provides Update on WPD101, a Drug Candidate Targeting GBM Tumors

WPD Pharmaceuticals Licensor Announces New Independent In Vitro Testing Confirms Antiviral Activity of WP1122 in Coronavirus

WPD Pharmaceuticals Licensor Announces Updates on Annamycin and WP1066

WBIO - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités